Grants and Contributions:
Title:
Development of a Biological Therapeutic Drug to Reverse Alzheimer's Disease
Agreement Number:
899107
Agreement Value:
$350,000.00
Agreement Date:
Jan 2, 2018 - Mar 31, 2019
Description:
KalGene and its NRC partners have identified a novel biological agent against amyloid-beta for Alzheimer’s disease. The IRAP project will support the late-stage development of the drug candidate..
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H4P 2R2
Reference Number:
172-2018-2019-Q3-899107
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
830005526
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 68,000 dollars.
Amendment Date
Dec 14, 2018
Recipient's Legal Name:
Kalgene Pharmaceuticals Inc.
Federal Riding Name:
Mount Royal
Federal Riding Number:
24052
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: